Project Description


While allergic airway inflammation is known to be the major underlying cause of asthma, there are few methods of measuring it. Evaluating airway inflammation using induced sputum or airway biopsy is expensive, time consuming, and often not readily available.

The NIOX MINO® sheds new light on asthma diagnosis and management – the device is designed to measure airway inflammation at the point of care. Patients with allergic airway inflammation generally have higher than normal levels of nitric oxide (NO) in their exhaled breath. By measuring the concentration of NO in an exhaled breath (fractional exhaled nitric oxide or FeNO), clinicians can evaluate allergic airway inflammation in patients with underlying asthma.

The NIOX MINO® offers fast, precise and sensitive FeNO measurement that reacts rapidly in response to treatment or exacerbation of disease. It is a non-invasive test that offers more for day-to-day asthma diagnosis and management than any of the conventional lung function tests, while providing ease and convenience for patients.

Reasons to obtain a FeNO measurement

Assist in diagnosis

  • Diagnose eosinophilic airway inflammation
  • Support the diagnosis of asthma when objective evidence is lacking
  • Help determine when respiratory symptoms are not due to asthma
  • Determine whether uncontrolled allergic airway inflammation is contributing to poor asthma control

 Aid in treatment

  • Determine the likelihood of steroid responsiveness
  • Guide stepwise changes in anti-inflammatory medication (step-down dosing, step-up dosing, or discontinuation)

 Assist in monitoring control and adherence

  • Establish baseline FeNO level during a period of clinical stability, which can be subsequently monitored
  • Help determine whether patients are adhering to prescribed corticosteroid treatment


Manufactured by: Aerocrine AB, Sweden